Trial to assess safety and tolerability of mavorixafor in combination with ibrutinib in WM patients with MYD88/CXCR4 double mutation associated with treatment resistance CAMBRIDGE, MA, UNITED STATES – Dec 30, 2019 – X4 Pharmaceuticals, Inc. (Nasdaq: XFOR),...
BOSTON–(BUSINESS WIRE)– Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 study of...
– GRAVITAS-301 results show that treatment with itacitinib in combination with corticosteroids did not statistically improve overall response rate or non-relapse mortality compared to placebo plus corticosteroids WILMINGTON, Del.–(BUSINESS...
CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928...
A study published today in STEM CELLS Translational Medicine indicates that treating cryptoglandular perianal fistula with autologous adipose-derived stem cells (ASCs) is safe and can in fact promote long-term and sustained healing. The FISPAC Collaborative Group A...
Email
Text